Loading
Translational breast oncologist who co-leads the I-SPY2 platform trial and helped show immunotherapy works in early TNBC.
Lajos Pusztai (Yale Cancer Center) co-leads the I-SPY2 adaptive neoadjuvant platform, whose durvalumab and pembrolizumab arms provided the first randomised evidence that checkpoint inhibitors raise pathological complete response in triple-negative breast cancer, before KEYNOTE-522 confirmed it. He led the SWOG S1418 adjuvant pembrolizumab trial and has published widely on immune gene signatures. His current focus is response-adapted de-escalation.
Shares Yale Cancer Center / Smilow Cancer Hospital, Pembrolizumab, Immune checkpoint inhibitors.
Shares Durvalumab, Pembrolizumab, Immune checkpoint inhibitors.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC), Pembrolizumab, Immune checkpoint inhibitors.
Shares Triple-negative breast cancer (TNBC), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc.
Shares Triple-negative breast cancer (TNBC), Pembrolizumab and the tag tnbc.
Shares Triple-negative breast cancer (TNBC), Immune checkpoint inhibitors and the tag tnbc.
Shares Triple-negative breast cancer (TNBC), Pembrolizumab and the tag tnbc.